RecruitingPhase 1NCT06616636
A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)
Studying Myelodysplastic neoplasm with increased blasts
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- M.D. Anderson Cancer Center
- Principal Investigator
- Courtney DiNardo, MDM.D. Anderson Cancer Center
- Intervention
- Azacitidine(drug)
- Enrollment
- 24 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2025 – 2029
Study locations (1)
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Collaborators
Memorial Sloan Kettering Cancer Center (MSK) · PMV Pharmaceuticals, Inc
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06616636 on ClinicalTrials.govOther trials for Myelodysplastic neoplasm with increased blasts
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06138587Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell TransplantationDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE2NCT04994808Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid LeukemiaFred Hutchinson Cancer Center
- RECRUITINGPHASE2NCT04741945Repurposing Metformin As a Leukemia-preventive Drug in CCUS and LR-MDSKirsten Grønbæk
- RECRUITINGPHASE1NCT04275518A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.Ascentage Pharma Group Inc.
- ACTIVE NOT RECRUITINGPHASE1NCT03974217Talazoparib for Cohesin-Mutated AML and MDS With Excess BlastsDana-Farber Cancer Institute
- ACTIVE NOT RECRUITINGPHASE3NCT03682536A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA NaïveCelgene
- RECRUITINGPHASE1, PHASE2NCT03471260Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic MalignanciesM.D. Anderson Cancer Center
- ACTIVE NOT RECRUITINGPHASE1NCT02477878Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic TransplantBellicum Pharmaceuticals
See all trials for Myelodysplastic neoplasm with increased blasts →